Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025CellsOpen Access

CRISPR-Powered Liquid Biopsies in Cancer Diagnostics

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJoshua R. SlatteryYNYe NaungBKBernd H. Kalinna

Discussion

Loading...

Member takes

Overview

This review demonstrates the effectiveness of CRISPR diagnostics for cancer biomarkers, suggesting advancements for point-of-care testing.

Key Points

  • Using CRISPR diagnostics improves the detection of cancer biomarkers in liquid biopsies, enabling earlier diagnosis.
  • Markers in peripheral blood samples include circulating tumour nucleic acids, which are critical for cancer diagnostics.
  • The integration of nucleic acid amplification with CRISPR enhances sensitivity and specificity comparable to established laboratory techniques.
  • CRISPR assays present unique advantages for point-of-care applications, facilitating faster and easier development than traditional assays.

Cite This Study

Slattery et al. (2025) studied this question.

synapsesocial.com/papers/68de5da783cbc991d0a20e8ahttps://doi.org/10.3390/cells14191539
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap2026
  2. 2CRISPR diagnostics: from trans-nuclease activity to cancer diagnosis2026
  3. 3Overcoming Liquid Biopsy Barriers: Nucleic Acid Biosensors Integrating DNA Nanotechnology and CRISPR−Cas System for Cancer Precision Theranostics2026
  4. 4Crispr Powered Diagnostics For Rapid Disease Detection In Resource Limited Settings2026
  5. 5Advances in CRISPR Based Biosensing Strategies for Cancer Diagnosis2024 · 1 citations